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Parkinson’s disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the 
substantia nigra pars compacta. Furthermore, oxidative stress plays a role in PD, causing or contributing 
to the neurodegenerative process. Currently PD has only symptomatic treatment and still nothing can 
be done to stop the degenerative process of the disease. This study aimed to comparatively evaluate 
the antioxidant capacity of pramipexole, selegeline and amantadine in different in vitro studies and 
to offer possible explanations on the molecular antioxidant mechanisms of these drugs. In vitro, the 
antioxidant capacity of the drugs was assessed by the ability of antiparkinsonian drugs to decrease or 
scavenge ROS in the neutrophil respiratory burst, ability of antiparkinsonian drugs to donate hydrogen 
and stabilize the free radical 2,2-diphenyl-1-picryl-hydrazyl (DPPH•), to scavenge 2,2’-azino-di-(3-
ethylbenzthiazoline-6-sulphonic acid (ABTS+) and evaluation of the ferric reducing antioxidant power 
(FRAP). This study demonstrated that both pramipexole and selegiline, but not amantadine, have 
antioxidant effects in vitro by scavenging superoxide anion on the respiratory burst, donating electron 
in the ABTS+ assay and presenting ferric reduction antioxidant power. This chemical structure-related 
antioxidant capacity suggests a possible neuroprotective mechanism of these drugs beyond their already 
recognized mechanism of action.
Uniterms: Parkinson´s disease. Oxidative stress. Antiparkinsonian drugs/in vitro studies. Antioxidants.
A doença de Parkinson (DP) é caracterizada pela degeneração progressiva dos neurônios dopaminérgicos 
na substância negra pars compacta. Além disso, o estresse oxidativo, presente nesta doença, causa ou 
contribui para o processo neurodegenerativo. Atualmente, a DP tem apenas tratamento sintomático e ainda 
nada pode ser feito para interromper o processo degenerativo. Este estudo teve como objetivo avaliar, 
comparativamente, a capacidade antioxidante do pramipexol, selegilina e amantadina em diferentes testes 
in vitro e oferecer possíveis explicações sobre os mecanismos moleculares antioxidantes destes fármacos. 
Avaliou-se a atividade antioxidante dos fármacos através da capacidade em diminuir ou sequestrar espécies 
reativas de oxigênio no burst respiratório, da capacidade em doar hidrogênio e estabilizar o radical livre 
2,2-difenil-1-picril-hidrazil (DPPH•), de remover o radical 2,2’-azino-di-(3-etilbenzotiazolina-6-sulfônico 
(ABTS+) e da verificação do poder redutor/antioxidante do ferro (FRAP). Este estudo demonstrou que 
tanto o pramipexol como a selegilina, mas não a amantadina, possuem efeitos antioxidantes in vitro por 
eliminar o ânion superóxido no burst respiratório, doar elétrons no método ABTS e apresentar poder 
redutor sobre o ferro (FRAP). Essa capacidade antioxidante pode estar relacionada com a estrutura 
química desses medicamentos, sugerindo possíveis mecanismos neuroprotetores destes fármacos além 
de seus mecanismos de ação já conhecidos.
Unitermos: Doença de Parkinson. Estresse oxidativo. Fámacos antiparkinsonianos/testes in vitro. 
Antioxidantes.
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INTRODUCTION
Parkinson disease (PD) is the second most prevalent 
neurodegenerative disorder, affecting 1 to 2% of the 
population above 65 years of age and, approximately, 4% 
of individuals above 85 years (Perfeito, Oliveira, Rego, 
2012). The clinical symptoms of PD manifest as the loss 
of initiation and control of movement, which appear after 
a substantial loss of dopaminergic neurons (50-60%) in the 
substantia nigra pars compacta (SNpc). As a consequence 
of this cell loss, dopamine in striatum is depleted by 
70–80% (Datla et al., 2007; Mercado, Valde, Hetz, 2013).
The pharmacological treatment of PD has not 
changed substantially in the past 30 years and dopamimetic 
therapy is the gold standard. L-dopa and dopaminergic 
agonists are the main drugs used but a series of enzyme 
inhibitors, (peripheral decarboxylase inhibitors, catechol-
O-methyl transferase inhibitors, and monoamine 
oxidase-B inhibitors, MAO-B) also support dopamimetic 
therapy (Dexter, Jenner, 2013; Nolan, Sullivan, Toulouse, 
2013; Obeso et al., 2010).
The cause of nigral cell death in PD remains unclear, 
yet several hypotheses have emerged in the scientific 
literature. The “oxidative stress hypothesis” postulates 
that a disruption in the balance between antioxidant 
molecules and reactive oxygen (ROS) and reactive 
nitrogen species (RNS) leads to oxidative damage of 
cellular macromolecules and, consequently, to cell death. 
This hypothesis is based on the fact that the oxidative 
metabolism of dopamine generates hydrogen peroxide 
(H2O2) and others ROS, exposing dopaminergic neurons 
of the SNpc to chronic oxidative stress (Drechsel, Patel, 
2008; Liddell et al., 2013). Oxidative stress is evidenced in 
PD by the increased lipid peroxidation and DNA damage 
in the substantia nigra and increased encephalic protein 
oxidation (Surendran, Rajasankar, 2010).
Pramipexole is a synthetic aminobenzothiazole 
derivative with selective agonistic activity on D2 and 
D3 receptors. Selegiline is a MAO-B inhibitor, reducing 
dopamine catabolism at nerve terminals in the basal ganglia. 
Amantadine is a synthetic tricyclic amine that belongs to the 
class of aminoadamantanes (Deleu, Northway, Hanssens, 
2002). The mechanism of action of amantadine probably 
involves enhancement of dopaminergic transmission; 
a mild antimuscarinic activity and a noncompetitive 
antagonism of the NMDA (N-methyl D-aspartate) receptor 
(Boll, Zubeldia, Rios, 2011). Even though the mechanisms 
by which antiparkinsonian drugs increase dopaminergic 
or decrease cholinergic neurotransmissions are well 
understood, the literature misses information regarding 
mechanisms involved in a possible intrinsic antioxidant 
activity that the antiparkinsonian drugs might have that 
could, consequently, collaborate to their therapeutical 
efficacy. This study aimed to comparatively evaluate 
the antioxidant capacity of three antiparkinsonian drugs 
(pramipexole, selegeline and amantadine) that can cross 
the hematoencephalic barrier in different in vitro studies 
and to offer possible explanations on the molecular 
antioxidant mechanisms of these drugs.
MATERIAL AND METHODS
Chemicals
The drugs used were: amantadine hydrochloride 
(Mantidan™, Eurofarma, Brazil), selegiline hydrochloride 
(Jumexil™, Chiesi, Brazil), pramipexole dihydrochloride 
(Sifrol™, Boehringer-Ingelheim, Brazil). The drugs were 
macerated and dissolved in dimethylsulfoxide (DMSO: 
Synth, Brazil). The reagents used for the assays were: 
luminol (Acros, USA) and phorbolmyristate acetate 
(PMA), histopaque, 2,2′-azinobis(3-ethylbenzothiazoline-
6-sulfonic acid) (ABTS), 2,2-diphenyl-1-picrylhydrazyl 
(DPPH•), 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ), trolox, 
all from Sigma-Aldrich, USA. All other reagents were of 
the highest grade available commercially.
Antioxidant activity
ROS production by neutrophils (respiratory burst)
ROS production by neutrophils was evaluted by 
chemiluminescence according to an adaptation of the 
method described by Freitas et al. (2008) and Huber, 
Krötz-fahning, Hock (2006) in a multilabel plate reader 
(Victor X-3, PerkinElmer™, USA). Human neutrophils 
were isolated from whole blood through gradient density 
centrifugation. Neutrophil burst was induced by PMA 
in the presence of 10-4 M of pramipexole, selegiline, 
amantadine or PBS (control group). Even though DMSO 
was used to dissolve the test drugs it does not influence 
respiratory burst as demonstrated in pilot experiments 
conducted in our laboratory (data not show). The reaction 
medium in each well was composed by 200 mL neutrophils 
(2.5 X 106 cells/mL), 50 mL of luminol 20 mM, 10 mL of the 
solutions of the test drugs and 50 mL of PMA 5 mM. After 
fast homogenization, reading (response range between 
300-620 nm) was conducted for 60 min (one read/min) 
under a temperature of 30±1 °C. Results are expressed as 
count per minute (c.p.m.). Each experimental group was 
composed by at least 14 replicates. For statistical analysis, 
the peak value of each curve was used, independently of 
the time it occurred.
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Reduction of free radical DPPH
The measurement of free radical scavenging 
was conducted according to Blois, (1958), with some 
modifications. Antiparkinsonian drugs were added to the 
reaction mixture containing 1 mL 0.1 M acetate buffer 
(pH 5.5), 1 mL of ethanol and 0.5 mL of ethanolic solution 
of DPPH• 250 M. The drugs concentrations in the reaction 
were 0.002-0.05 mg/mL of pramipexole, 0.015-0.25 mg/mL 
of selegiline and 0.311-5.4 mg/mL of amantadine. The 
reduction of DPPH• radical was determined by the change 
in absorbance measured at 517 nm. The suppression of 
the colored radical results in absorbance decrease. The 
positive control was prepared in the absence of the test 
drugs in order to determine the maximum odd electrons 
of DPPH•, which was considered 100% of free radicals 
in the solution and used to calculate the hydrogen-
donating ability (%) of the drugs evaluated. The blank 
was prepared from the reaction mixture without DPPH• 
solution. Samples were analyzed in triplicate. The results 
were expressed as percentage of activity by the following 
equation:
Equation I: % of activity = [1- (sample absorbance/ 
control absorbance)] x 100.
ABTS free radical scavenging assay
The ability to scavenge the ABTS+ free radical was 
carried out according to Sánchez-Gonzáles, Jiménez-
Escrig, Saura-Calixto (2005) with some modifications. 
ABTS+ solution was obtained after the reaction of 7 mM 
ABTS with 2.45 mM potassium persulphate. This solution 
was diluted in phosphate buffer (pH 7.4, 0.1 M) until it 
reached an absorbance of 0.7 to 0.8 at 730 nm. Different 
concentrations of pramipexole 0.001-0.03 mg/mL, 
selegil ine 0.015-0.225 mg/mL and amantadine 
0.311-5.4 mg/mL were evaluated. The suppression of the 
colored radical on the medium was monitored through the 
decrease in absorbance. The positive control was prepared 
in the absence of the test drugs and was considered 100% 
of free radicals in the solution, which was used to calculate 
the scavenging ability of the drugs. The blank was 
prepared with a solution of potassium persulfate diluted 
in phosphate buffer. Samples were performed in triplicate 
and the ability of scavenging ABTS+ was calculated by 
equation I.
Ferric reducing antioxidant power (FRAP test)
FRAP was evaluated according to Sánchez-
Gonzáles, Jiménez-Escrig, Saura-Calixto (2005) with 
some modifications. In this assay, antioxidants added to 
medium reduce the Fe+3TPTZ complex to form a blue-
colored Fe+2TPTZ complex, which results in an increase 
in the absorbance.
FRAP reagent was prepared with 2.5 mL of the 
solution of TPTZ (10 mM) in HCI (40 mM), 2.5 mL 
FeCl3.(6H2O) solution and 25 mL of acetate buffer 
(pH 3.6, 0.3Mm). The solution was incubated at 37 °C 
for 30 min. For the assay, 900 mL of FRAP reagent were 
added to 90 mL of water and 10 mL of trolox standard 
and 150 mL of pramipexole (0.164 mg/mL) or 100 mL 
of selegiline (0.573 mg/mL) or 180 mL of amantadine 
(19.23 mg/mL) in the reaction medium. After incubation 
at 37 °C for 30 minutes, measurements were obtained 
in a spectrophotometer at 595 nm. An analytical curve 
with different concentrations of trolox (4.0-20.0 mM) 
was used for subsequent calculation of results in mmol/L 
trolox equivalent mg/mL of the drugs. The positive control 
was prepared in the absence of the test drugs. The blank 
was prepared with a solution of FRAP reagent and water. 
Samples were performed in triplicate.
STATISTICAL ANALYSIS
Initially, an exploratory analysis was conducted 
with data from the respiratory burst in order to evaluate 
Gaussian distribution (Shapiro-Wilk test) and homogeneity 
of variance (Levene’s test). In the absence of normal 
distribution and homogeneity of variance, data were 
analyzed through the non-parametric test of Kruskal-
Wallis complemented with Dunn. Results are presented 
as median, minimum (min) and maximum (max) values 
considering the peak value of each curve.
The in vitro  concentration of pramipexole, 
selegiline and amantadine that caused 50% of DPPH and 
ABTS scavenging was considered the mean inhibitory 
concentration (IC50). The IC50 was determined by 
GraphPadPrism® software, version 3.02, using hyperbolic 
curve (one site binding hyperbole). On the FRAP the 
results obtained with the test-drugs were compared to 
trolox curve. Antioxidant activity results are presented as 
means ± standard error mean (SEM).
Results were considered statistically significant if 
P < 0.05.
RESULTS
Pramipexole and selegiline decrease ROS 
production by neutrophils
Figure 1A presents the chemiluminescence produced 
by PMA-stimulated neutrophils in the absence (Control) 
or presence of 10-4 M pramipexole, selegeline and 
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amantadine. Each curve was plotted with the median 
of at least 14 replicates. Kruskall-Wallis indicated a 
significant difference in the peak values of the kinetic 
curves (KW=28.9, p<0.0001). Dunn´s test revealed that 
the peak values obtained with both pramipexole and 
selegeline were significantly lower than control (Figure 
1B). Amantadine lacked antioxidant effect. As observed 
in Figure 1B, the control neutrophils have shown median 
c.p.m. of 87859 (76463 to 105561), whereas the values 
for pramipexole, selegeline and amantadine were, 
respectively: 24364 (23208 to 26404), 57418 (53884 to 
62901) and 78418 (74934 to 84717).
Free radical scavenging assays
The abili ty of pramipexole, selegiline and 
amantadine to scavenge ABTS+, DPPH• and FRAP was 
evaluated.
In the ABTS+ assay, both pramipexole and selegiline 
scavenged the positively charged ABTS+ radical in a 
concentration-dependent manner (Figure 2A and 2B). 
Pramipexole assay resulted in a linearity of R² 0.9749 
between 0.001 to 0.03 mg/mL. Maximum activity was 
found to be 99% at the concentration of 0.03 mg/mL and 
IC50 was 0.002 mg/mL. Selegiline assay showed a linearity 
of R² 0.9934 between 0.015 and 0.225 mg/mL. Maximum 
activity was 54% at the concentration of 0.225 mg/mL and 
IC50 was 0.191 mg/mL (Figure 2B). Amantadine did not 
present scavenging activity and the concentration-response 
curve parameters could not be calculated.
In the DPPH• assay any of the drugs presented 
scavenging activity (data not shown).
On FRAP assay, pramipexole (1mg/mL) reducing 
power was 11.8 ± 0.9 µmol/L trolox equivalent (n=3) and 
FIGURE 1 – Effect of antiparkinsonian drugs (10-4 M) on the 
activation of human neutrophils by PMA. Each group was 
composed by at least 14 replicates. A. Kinetic curves obtained 
each minute for 60 minutes. B. Box plot of the peak values 
on the kinetic curves. Data were analyzed by Kruskal-Wallis 
complemented with Dunn´s test. *p< 0.01 compared to control; 
**p< 0.001 compared to control. c.p.m. = count per minute.
FIGURE 2 -Free radical scavenging activity of pramipexole (A) and selegiline (B) in the ABTS+ assay. Data are means ± standard 
error mean (SEM) of triplicate values and are presented as percentage of inhibition relative to control.
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selegiline (1mg/mL) one was 8.9 ± 0.96 µmol/L trolox 
equivalent (n=3), demonstrating that pramipexole presents 
1.32-fold greater activity than selegiline. As observed in 
the other tests, amantadine lacked antioxidant response 
in this assay.
DISCUSSION
Over the past few decades a large volume of data 
generated from clinical studies, autopsies and in vitro 
and in vivo experimental models have suggested that 
nitrosative and oxidative stress play an important role 
in neurodegeneration of the substantia nigra associated 
with PD. ROS/RNS lead to molecular damage (lipid 
and protein oxidation, DNA damage) that can disrupt 
biological functions and ultimately induce neuronal death 
(Danielson, Andersen, 2008; Perfeito, Oliveira, Rego, 
2012).
To our knowledge this is the first time that a 
correlation between the possible antioxidant effects of 
pramipexole and selegiline with their chemical structure 
has been investigated. This study demonstrated that both 
pramipexole and selegiline, but not amantadine, have 
antioxidant effects in vitro by scavenging superoxide anion 
(O2•-) on the respiratory burst, donating electron in the 
ABTS+ assay and presenting ferric reduction antioxidant 
power. This antioxidant capacity suggests a possible 
neuroprotective mechanism of these drugs beyond their 
already recognized mechanism of antiparkinsonian effect.
Pramipexole and selegiline produced positive effects 
scavenging ABTS+ radical and presenting ferric reduction 
antioxidant power but lacked effect towards DPPH• 
radical. The antioxidant activity of these drugs may be 
due to reducing power related to their chemical structure.
Pramipexole is a dopaminergic agonist that consists 
of a fused bicyclic tetrahydrobenzothiazole (Figure 3) 
(Baumann et al., 2011). The antioxidant activity observed 
in the respiratory burst could have resulted from the 
neutralization of the O2•- by the release of one proton 
(H+) from the amino group (NH2) of pramipexole. After 
the donation, the radical can resonates with the thiazole 
ring whereas the neutralization of the superoxide radical 
would allow it to dissociate into H2O and O2. Moreover, 
pramipexole molecule also presents two secondary amine 
groups, which can donate the pair of electrons to neutralize 
ROS and induce the antioxidant activity observed in the 
ABTS+ and FRAP assays.
Our results corroborate studies from the literature 
that describe antioxidant activity for pramipexole both in 
vitro (Cassarino et al., 1998; Ferger, Teismann, Mierau, 
2000; Gu et al., 2004) and in vivo (Cassarino et al., 1998; 
Ferger, Teismann, Mierau, 2000; Le et al., 2000). In vitro, 
pramipexole reduced the levels of methylpyridinium 
ion (MPP+)-produced oxygen radicals in SH-SY5Y 
cells and it was also able to reduce Fenton reaction-
derived hydroxyl radical (Cassarino et al., 1998; Ferger, 
Teismann, Mierau, 2000). In vivo, pramipexole inhibited 
ROS production via decreased turnover of dopamine 
metabolism mediated by its action on dopaminergic 
autoreceptors. In addition, it also presented a direct 
scavenging activity and stimulated cellular glutathione 
peroxidase and catalase (Le et al., 2000) and reduced the 
levels of 6-hydroxydopamine-induced hydroxyl radical in 
the striatum (Ferger, Teismann, Mierau, 2000). In addition, 
it was demonstrated that pramipexole inhibited MPP+ ion-
induced lipid peroxidation in C57BL/6 mice (Zou et al., 
2000). Taken together, data seem to support an antioxidant 
activity for pramipexole, which could result from intrinsic 
characteristics of its molecule.
Selegiline is a selective irreversible inhibitor 
of MAO-B, the enzyme responsible for the oxidative 
metabolism of dopamine and which activity increases 
in the brain during aging and neurodegeneration. The 
inhibition of MAO-B can prevent ROS formation from 
dopamine metabolism. Some studies have described 
a neuroprotective effect of this drug independent of 
its inhibitory action on MAO (Boll, Zubeldia, Rios, 
2011; Follmer, 2013; Singh, Pillay, Choonara, 2007). 
Takahata et al. (2006) described that selegiline can 
decrease oxidative stress in nigrostriatum by augmenting 
the antioxidant capacity, i.e., increasing the activity of 
antioxidant enzymes (superoxide dismutase and catalase) 
and the level of glutathione in specific brain regions. 
Goverdhan, Sravanthi, Mamatha (2012) demonstrated 
that selegiline inhibited lipid peroxidation and increased 
endogenous antioxidant enzymes in brain samples of an 
Alzheimer disease mouse model. The results obtained in 
the present work suggest an intrinsic antioxidant ability 
of the selegiline molecule, which could be attributable 
to the propargylamine group (Figure 3). This group 
is formed by propargyl, containing the unit acetylene 
(alkyne), as well as by a tertiary amine. It is hypothesized 
that selegeline was able to reduce the respiratory burst 
through the release of a proton (H+) from the acetylenic 
unit that neutralized the O2•-. Moreover, the tertiary amine 
group could also have shared a pair of electrons and 
neutralized ROS, as observed in three out of four assays 
employed in this study. It is noteworthy that even though 
selegeline presented an intrinsic antioxidant activity, it 
was less effective than the one observed with pramipexole. 
Probably, the selegiline radical produced after the proton 
release is less stable compared to the pramipexole that 
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is stabilized by its functional groups. Hall et al. (1996) 
evaluated the oxidative degradation of pramipexole in an 
electrochemical cell. Pramipexole is readily susceptible 
for oxidation (i.e., ability to lose or possibly donate an 
electron) qualifying it as having antioxidant capability. 
However, this property has not been demonstrated for 
selegiline.
Amantadine lacked in vitro antioxidant activity in all 
the assays conducted in this study even though this drug 
also presents an amino (NH2) group (Figure 3). Our results 
support the importance of a conjugated system to stabilize 
the load (like pramipexole) because isolated groups (as 
observed in amantadine) do not result in antioxidant 
activity. Supporting the present results, Lupp et al. (1998) 
reported that amantadine presented the lowest in vitro 
antioxidant activity compared to others non-competitive 
N-methyl-D-aspartate (NMDA)-receptor antagonists.
Interestingly, pramipexole and selegiline failed to 
stabilize the radical DPPH•. A possible explanation for this 
lack of effect would be the low reactivity of this radical 
as well as steric hindrance caused by its bulky molecular 
structure (Prior, Wu, Schaich, 2005).
CONCLUSIONS
Both pramipexole and selegiline have shown in vitro 
antioxidant activity either in ABTS+ and FRAP assays as 
well as in respiratory burst assay, which is a more complex 
model. Although some studies have already pointed into 
this direction, the literature was lacking a comparative 
study among antiparkinsonian drugs as well as a discussion 
on the hypotheses that could explain the antioxidant 
mechanisms of these drugs. If the antioxidant activity of 
pramipexole and selegeline offers neuroprotection and 
contributes effectively in delaying PD progression is an 
open question that remains to be answered.
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